Adaptive Biotechnologies Corp
NASDAQ:ADPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adaptive Biotechnologies Corp
Intangible Assets
Adaptive Biotechnologies Corp
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
Intangible Assets
$1.7m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Intangible Assets
$15.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Danaher Corp
NYSE:DHR
|
Intangible Assets
$17.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
Waters Corp
NYSE:WAT
|
Intangible Assets
$558.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
17%
|
CAGR 10-Years
10%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Intangible Assets
$426m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Intangible Assets
$5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
30%
|
|
Adaptive Biotechnologies Corp
Glance View
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.
See Also
What is Adaptive Biotechnologies Corp's Intangible Assets?
Intangible Assets
1.7m
USD
Based on the financial report for Dec 31, 2025, Adaptive Biotechnologies Corp's Intangible Assets amounts to 1.7m USD.
What is Adaptive Biotechnologies Corp's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-30%
Over the last year, the Intangible Assets growth was -50%. The average annual Intangible Assets growth rates for Adaptive Biotechnologies Corp have been -37% over the past three years , -30% over the past five years .
